Advances in drug delivery for post-surgical cancer treatment

Lin-Lin Bu; Junjie Yan; Zejun Wang; Huitong Ruan; Qian Chen; Vivienne Gunadhi; R Bryan Bell; Zhen Gu

doi:10.1016/j.biomaterials.2019.04.027

Advances in drug delivery for post-surgical cancer treatment

Biomaterials. 2019 Oct:219:119182. doi: 10.1016/j.biomaterials.2019.04.027. Epub 2019 Apr 28.

Authors

Lin-Lin Bu¹, Junjie Yan², Zejun Wang³, Huitong Ruan³, Qian Chen³, Vivienne Gunadhi³, R Bryan Bell⁴, Zhen Gu⁵

Affiliations

¹ Department of Bioengineering, University of California, Los Angeles, CA, 90095, USA; Jonsson Comprehensive Cancer Center and Center for Minimally Invasive Therapeutics, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA; The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, and Department of Oral Maxillofacial Head Neck Oncology, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, 430079, China.
² Molecular Imaging Center, Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China.
³ Department of Bioengineering, University of California, Los Angeles, CA, 90095, USA; Jonsson Comprehensive Cancer Center and Center for Minimally Invasive Therapeutics, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.
⁴ Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, 97213, USA.
⁵ Department of Bioengineering, University of California, Los Angeles, CA, 90095, USA; Jonsson Comprehensive Cancer Center and Center for Minimally Invasive Therapeutics, California NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA. Electronic address: [email protected].

PMID: 31415954
DOI: 10.1016/j.biomaterials.2019.04.027

Abstract

Surgery remains a primary modality of treatment for the majority of solid tumor malignancies. While advancements in surgical technique and instrumentation have improved the quality of life for cancer patients, local tumor recurrence and metastasis after surgery remain challenging and result in a high rate of mortality and decrease quality of life. It is therefore urgent to explore effective methods to eliminate residual microscopic disease in the surgical site and/or circulating tumor cells (CTCs) to inhibit tumor recurrence and minimize the risk of distant metastasis. Recently, advances in bioengineering technology have facilitated the development of drug delivery systems (DDSs) for the release of chemotherapy and immunotherapy agents, which could be used to enhance the effectiveness of surgical resection. In this review, we survey the rapidly evolving fields of local and systemic controlled DDSs, utilizing a variety of formulations and devices, such as implantable wafers, injectable/sprayable hydrogels, micro/nanoparticles, and cellular particles. Opportunities and challenges for the clinical translations of these delivery systems are also discussed.

Keywords: Cancer treatment; Drug delivery; Immunotherapy; Local delivery; Surgery.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Drug Delivery Systems / trends*
Humans
Hydrogels / chemistry
Immunotherapy
Nanotechnology
Neoplasms / drug therapy*
Neoplasms / surgery*

Substances

Hydrogels